Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the U.S., and South America.

Cipher is focused on building strategic sales and distribution partnerships, out licensing products and selective investments in drug development to assemble a broad portfolio of prescription products that serve unmet medical needs.